Kodiak Sciences Inc. Stock Price, News & Analysis

Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q3 2022 results, highlighting significant advancements in its clinical programs for tarcocimab tedromer, aimed at treating retinal diseases. The company anticipates topline results from key Phase 3 studies in 2023. Financially, Kodiak ended the quarter with $537.4 million in cash but posted a net loss of $77.0 million, increasing from $67.5 million year-over-year. R&D expenses rose to $61.7 million, reflecting higher stock-based compensation, while G&A expenses also grew significantly to $17.8 million.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing therapeutics for retinal diseases, will present at the 2022 Morgan Stanley Healthcare Conference in New York, on September 14, 2022, at 1:05 PM PT. The event will be available for live streaming on Kodiak's website and can be replayed afterwards. Kodiak leverages its ABC Platform™ to create innovative therapies, including its lead candidate, tarcocimab tedromer, targeting significant retinal diseases such as wet age-related macular degeneration and diabetic eye diseases.

Kodiak Sciences Inc. (Nasdaq: KOD) announced that results from the Phase 3 BEACON study of its investigational therapy, tarcocimab tedromer (KSI-301), will be presented at two key ophthalmology conferences: the EURETINA Congress in Hamburg and the American Academy of Ophthalmology Meeting in Chicago. The BEACON study involved 568 patients with retinal vein occlusion and demonstrated that tarcocimab achieved non-inferior visual acuity compared to aflibercept, while allowing for doubled treatment intervals. The company aims to utilize these results for potential regulatory approval.

Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q2 2022 results, highlighting significant advancements in its tarcocimab tedromer (KSI-301) clinical program. The BEACON study demonstrated non-inferior visual acuity gains, establishing a strong foundation for future studies in diabetic macular edema (GLEAM, GLIMMER) and wet AMD (DAYLIGHT). Despite robust clinical progress, the company reported a net loss of $90.6 million, driven by increased R&D and G&A expenses. Kodiak ended Q2 with $597.9 million in cash, crucial for supporting ongoing trials and operations.

Kodiak Sciences (KOD) announced positive outcomes from its BEACON Phase 3 study of tarcocimab tedromer (KSI-301) for retinal vein occlusion (RVO). Tarcocimab met its primary endpoint, showing non-inferior visual acuity gains compared to aflibercept while extending the treatment interval from monthly to every two months. The study involved 568 patients and demonstrated a favorable safety profile with minimal intraocular inflammation. These results may support future regulatory applications and are expected to impact ongoing studies in diabetic macular edema.

Kodiak Sciences (Nasdaq: KOD) announced the completion of enrollment in its GLOW Phase 3 clinical trial for tarcocimab tedromer (KSI-301), targeting non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema. This investigational therapy aims to provide significant treatment opportunities by potentially extending administration intervals to six months, addressing the treatment burden of current therapies. The trial involves approximately 240 patients, with primary results expected in a year.

Kodiak Sciences Inc. (Nasdaq: KOD) will present at the Jefferies Global Healthcare Conference on June 9, 2022, at 11:30 a.m. PT. The live webcast will be accessible on Kodiak's website and available for replay after the event. Kodiak focuses on developing therapies for retinal diseases and is known for its ABC Platform™, which combines antibody-based and chemistry-based therapies. Their lead candidate, KSI-301, targets retinal vascular diseases. More about Kodiak can be found on their website.

Kodiak Sciences Inc. (Nasdaq: KOD) and Lonza have inaugurated a bioconjugation facility in Lonza's Ibex^® Dedicate Biopark in Switzerland. This facility will support the potential commercial launch of KSI-301, Kodiak's lead product for retinal diseases. Expected to produce over 10 million doses annually, the facility strengthens collaboration between Kodiak and Lonza, creating 12 new jobs at Kodiak and 70 at Lonza. KSI-301 is currently undergoing Phase 3 trials for multiple retinal conditions, with plans to file a Biologics License Application pending successful results.

Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q1 2022 results with a net loss of $95.7 million ($1.83 per share), increasing from a net loss of $50.4 million in Q1 2021. R&D expenses rose to $76.2 million due to clinical trial costs and manufacturing activities. Despite challenges in its Phase 2b/3 wet AMD study, Kodiak remains optimistic about its KSI-301 program, anticipating four Phase 3 study readouts in 2022 and 2023. The company ended the quarter with $671.7 million in cash, maintaining a strong cash position for ongoing developments.